Objective—To determine efficacy of treatment with a
combination febantel-praziquantel-pyrantel product,
with or without vaccination with a commercial Giardia
vaccine, in dogs with naturally occurring giardiasis.
Animals—16 Beagles naturally infected with Giardia
Procedures—During phase 1, 6 dogs were treated
with the parasiticide for 3 days (4 were also vaccinated).
Four weeks later, all 6 dogs were treated with the
parasiticide again for 5 days and were bathed and
moved to clean cages after the last treatment (phase
2). Nine dogs were treated with the parasiticide for 3
(n = 4) or 5 (5) days and bathed and moved to clean
cages after the last treatment (phase 3). Fecal samples
were collected twice weekly for 24 days after
treatment and tested for cysts with a quantitative zinc
sulfate flotation technique and for Giardia antigen
with an immunoassay.
Results—Dogs in phase 1 were all shedding cysts
again by day 24. In phase 2, only 1 dog shed cysts
after treatment, and shedding was transient (day 17).
In phase 3, neither cysts nor antigen was detected in
fecal samples from 2 of 4 dogs treated for 3 days and
4 of 5 dogs treated for 5 days. In 18 of 57 (31.6%)
fecal samples, cysts were seen, but results of the
immunoassay were negative.
Conclusions and Clinical Relevance—Results suggest
that when a combination febantel-praziquantelpyrantel
product is used to treat dogs with giardiasis,
bathing and changing the environment after treatment
may be more important in preventing recurrence
than duration of treatment. (J Am Vet Med
OBJECTIVE To evaluate effects of simultaneous intra-articular and IV injection of autologous adipose-derived stromal vascular fraction (SVF) and platelet-rich plasma (PRP) to dogs with osteoarthritis of the hip joints.
PROCEDURES Dogs with osteoarthritis of the hip joints that caused signs of lameness or discomfort were characterized on the basis of results of orthopedic examination, goniometry, lameness score, the Canine Brief Pain Inventory (CBPI), a visual analogue scale, and results obtained by use of a pressure-sensing walkway at week 0 (baseline). Dogs received a simultaneous intraarticular and IV injection of SVF and PRP or a placebo. Dogs were examined again 4, 8, 12, and 24 weeks after injection.
RESULTS CBPI scores were significantly lower for the treatment group at week 24, compared with scores for the control group. Mean visual analogue scale score for the treatment group was significantly higher at week 0 than at weeks 4, 8, or 24. Dogs with baseline peak vertical force (PVF) in the lowest 25th percentile were compared, and the treatment group had a significantly higher PVF than did the control group. After the SVF-PRP injection, fewer dogs in the treated group than in the control group had lameness confirmed during examination.
CONCLUSIONS AND CLINICAL RELEVANCE For dogs with osteoarthritis of the hip joints treated with SVF and PRP, improvements in CBPI and PVF were evident at some time points, compared with results for the control group.
Objective—To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows.
Sample—26 studies published in peer-reviewed journals or reviewed by a regulatory agency.
Procedures—To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC).
Results—For cows treated with rbST-Zn, mean milk, 3.5% fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4%, and pregnancy proportion for the duration of the trial was reduced by 5.5% for rbST-Zn–treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling.
Conclusions and Clinical Relevance—Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.